Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):1115; doi:10.1093/jnci/96.15.1115
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

10-Year Results of Adjuvant Therapy Trial in Colon Cancer

Investigators from the National Surgical Adjuvant Breast and Bowel Project C-01 trial for patients with colon adenocarcinoma reported in 1988 that, for patients with resected Dukes' stage B and C colon cancer, compared with surgery alone, postoperative chemotherapy with semustine, vincristine, and 5-fluorouracil was associated with better 5-year disease-free and overall survival and that postoperative immunotherapy with bacillus Calmette-Guérin was associated with better 5-year overall survival. Smith et al. (p. 1128) now provide a 10-year update of this trial. They found no difference in . . . [Full Text of this Article]

Akt Phosphorylation, Gefitinib, and NSCLC

HER-2/neu Amplification and Response to Paclitaxel

HDL Cholesterol and Breast Cancer Risk

E3 Ubiquitin Ligase Receptor, {beta}-Catenin, and NF-{kappa}B

Liposomes, Immune Cell Function, and Neuroblastoma